CCRC - Certified Clinical Research Coordinator Participant Safety & AE Reporting Questions and Answers

Question 1

A study participant in a clinical trial for a new hypertension medication reports a persistent, severe headache.
The headache is listed in the Investigator's Brochure as a possible side effect.
According to ICH GCP guidelines, how should this event be classified?

Accepted Answer

As an Adverse Event (AE).

Answer

As a Serious Adverse Event (SAE) because it is severe.

Answer

As an Unanticipated Problem Involving Risks to Subjects or Others (UPIRSO).

Answer

As a protocol deviation since the event was expected.

Question 2

A Clinical Research Coordinator (CRC) is notified that a study participant has been hospitalized due to a suspected reaction to the investigational drug. According to FDA regulations for IND trials, what is the maximum timeframe for the sponsor to report this unexpected fatal or life-threatening suspected adverse reaction to the FDA?

Accepted Answer

As soon as possible, but no later than 7 calendar days.

Answer

Within 24 hours of the site becoming aware of the event.

Answer

Within 10 working days.

Answer

No later than 15 calendar days.

Question 3

Which of the following is a primary responsibility of the Clinical Research Coordinator (CRC) in the management of adverse events?

Accepted Answer

Ensuring accurate and timely documentation of the event in the source documents and Case Report Forms (CRFs).

Answer

Determining the final causality assessment of the event.

Answer

Informing the FDA directly of all Serious Adverse Events.

Answer

Modifying the protocol to mitigate future risks.

Question 4

During a Phase III trial, a participant experiences an allergic reaction resulting in anaphylactic shock, which requires emergency intervention and hospitalization. This specific type of reaction was not previously identified in the Investigator's Brochure. This event should be categorized as a:

Accepted Answer

Suspected Unexpected Serious Adverse Reaction (SUSAR).

Answer

Serious Adverse Event (SAE) only.

Answer

Non-serious Adverse Drug Reaction (ADR).

Answer

Protocol Violation.

Question 5

What key factor distinguishes a 'Serious Adverse Event' (SAE) from a non-serious adverse event according to ICH GCP guidelines?

Accepted Answer

The outcome or consequence of the event meeting specific criteria.

Answer

The severity grade of the event (e.g., mild, moderate, severe).

Answer

The certainty of the event's relationship to the investigational product.

Answer

The frequency of the event's occurrence within the study population.

Question 6

A research participant reports feeling nauseous after taking the investigational product. The CRC reviews the protocol and informed consent form, noting that nausea is a known and expected side effect. What is the CRC's most appropriate immediate next step?

Accepted Answer

Submit a Serious Adverse Event report to the sponsor.

Answer

Report the event to the IRB as an Unanticipated Problem within 24 hours.

Answer

Instruct the participant to immediately discontinue the investigational product.

Answer

Document the event, including its severity and duration, in the participant's source document.

A study participant in a clinical trial for a new hypertension medication reports a persistent, severe headache.The headache is listed in the Investigator's Brochure as a possible side effect.According to ICH GCP guidelines, how should this event be classified?

A study participant in a clinical trial for a new hypertension medication reports a persistent, severe headache.
The headache is listed in the Investigator's Brochure as a possible side effect.
According to ICH GCP guidelines, how should this event be classified?